STAT+: At ESMO, AstraZeneca and Gilead square off in triple-negative breast cancer
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
BERLIN \u2014 Patients with a highly aggressive form of breast cancer will likely have new treatment options for the first time in years after AstraZeneca and Gilead Sciences both presented successful trial results here Sunday, dual achievements that will also leave clinicians having to figure out which drug to choose when treating triple-negative tumors.\u00a0<\/p>\n
Both studies tested what\u2019s known as an antibody-drug conjugate \u2014 essentially, a next-generation type of chemotherapy<\/a> \u2014 compared to traditional chemotherapy regimens as a first-line medicine in patients with metastatic triple-negative breast cancer who couldn\u2019t receive an immunotherapy. The women largely weren\u2019t eligible for treatments like checkpoint inhibitors because their tumors did not express the protein that the drugs target. For these patients, there hasn\u2019t been a new first-line drug approved in over a decade.\u00a0<\/p>\n Researchers were already going to be comparing the results of the two Phase 3 studies in the difficult-to-treat tumors, but the stakes were upped with the trials being presented back-to-back here at the European Society for Medical Oncology\u2019s annual conference. A single discussant also analyzed the results together, parsing the outcomes for Gilead\u2019s Trodelvy as well as for Datroway, made by AstraZeneca and its partner Daiichi Sankyo.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n